0
Skip to Content
NMD Pharma
Home
About NMD Pharma
Management team
Our team
Board
Founders
Pipeline
Science
Neuromuscular diseases
Insights
Scientific publications
Information for patients
Spinal Muscular Atrophy
Myasthenia Gravis
Charcot Marie Tooth Disease
Press releases
Events
Other news
Investors
Your career
Find your job
Contact
NMD Pharma
Home
About NMD Pharma
Management team
Our team
Board
Founders
Pipeline
Science
Neuromuscular diseases
Insights
Scientific publications
Information for patients
Spinal Muscular Atrophy
Myasthenia Gravis
Charcot Marie Tooth Disease
Press releases
Events
Other news
Investors
Your career
Find your job
Contact
Home
Folder: About
Back
About NMD Pharma
Management team
Our team
Board
Founders
Folder: R&D
Back
Pipeline
Science
Neuromuscular diseases
Insights
Scientific publications
Folder: Patients & Clinical Trials
Back
Information for patients
Spinal Muscular Atrophy
Myasthenia Gravis
Charcot Marie Tooth Disease
Folder: News
Back
Press releases
Events
Other news
Investors
Folder: Careers
Back
Your career
Find your job
Contact
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
Press release Stine Krag Brunvold 12/14/22 Press release Stine Krag Brunvold 12/14/22

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

Read More
Thomas Holm Pedersen, will be participating in the 7th Annual Nordic American Life Science Conference
Other news Stine Krag Brunvold 12/7/22 Other news Stine Krag Brunvold 12/7/22

Thomas Holm Pedersen, will be participating in the 7th Annual Nordic American Life Science Conference

Read More
Today is International Day of Persons with Disabilities
Other news Stine Krag Brunvold 12/3/22 Other news Stine Krag Brunvold 12/3/22

Today is International Day of Persons with Disabilities

Read More
We have been awarded Entrepreneur of the Year in the Life Sciences category by EY</a> Denmark!
Other news Stine Krag Brunvold 11/24/22 Other news Stine Krag Brunvold 11/24/22

We have been awarded Entrepreneur of the Year in the Life Sciences category by EY Denmark!

Read More
NMD Pharma will be at the Life Science Career Fair Aarhus 22
Other news Stine Krag Brunvold 11/24/22 Other news Stine Krag Brunvold 11/24/22

NMD Pharma will be at the Life Science Career Fair Aarhus 22

Read More
NMD Pharma is attending BIO Europe</a>
Other news Stine Krag Brunvold 10/24/22 Other news Stine Krag Brunvold 10/24/22

NMD Pharma is attending BIO Europe

Read More
Today we are able to announce positive topline data from our Phase I/IIa clinical trial of NMD670 in patients with Myasthenia Gravis
Events Stine Krag Brunvold 10/11/22 Events Stine Krag Brunvold 10/11/22

Today we are able to announce positive topline data from our Phase I/IIa clinical trial of NMD670 in patients with Myasthenia Gravis

Read More
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
Press release Stine Krag Brunvold 10/11/22 Press release Stine Krag Brunvold 10/11/22

NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis

Read More
Thomas Holm Pedersen speaks at The First Nordic Conference on Myasthenia Gravis
Other news Stine Krag Brunvold 9/30/22 Other news Stine Krag Brunvold 9/30/22

Thomas Holm Pedersen speaks at The First Nordic Conference on Myasthenia Gravis

Read More
FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis
Press release Stine Krag Brunvold 9/27/22 Press release Stine Krag Brunvold 9/27/22

FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis

Read More
Thomas Holm Pedersen speaks at The Global CMT Research Convention
Other news Stine Krag Brunvold 9/16/22 Other news Stine Krag Brunvold 9/16/22

Thomas Holm Pedersen speaks at The Global CMT Research Convention

Read More
The INCUBA Awards
Other news Stine Krag Brunvold 9/7/22 Other news Stine Krag Brunvold 9/7/22

The INCUBA Awards

Read More
NMD Pharma will be at LSX Nordic Congress
Other news Stine Krag Brunvold 9/6/22 Other news Stine Krag Brunvold 9/6/22

NMD Pharma will be at LSX Nordic Congress

Read More
CMT Awareness Month in the US
Other news Stine Krag Brunvold 9/1/22 Other news Stine Krag Brunvold 9/1/22

CMT Awareness Month in the US

Read More
NMD Pharma at ICFSR 2022 - Symposium 4 - Part 1
Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22

NMD Pharma at ICFSR 2022 - Symposium 4 - Part 1

Read More
NMD Pharma at ICFSR 2022 - Symposium 4 - Part 2
Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22

NMD Pharma at ICFSR 2022 - Symposium 4 - Part 2

Read More
NMD Pharma at ICFSR 2022 - Symposium 4 - Part 3
Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22

NMD Pharma at ICFSR 2022 - Symposium 4 - Part 3

Read More
NMD Pharma at ICFSR 2022 - Symposium 4 - Part 4 - Q&amp;A
Events Stine Krag Brunvold 8/16/22 Events Stine Krag Brunvold 8/16/22

NMD Pharma at ICFSR 2022 - Symposium 4 - Part 4 - Q&A

Read More
Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Eden
Insights Stine Krag Brunvold 8/8/22 Insights Stine Krag Brunvold 8/8/22

Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Eden

Read More
What happens day-to-day in the life of a Research Scientist at NMD Pharma?
Other news Stine Krag Brunvold 8/2/22 Other news Stine Krag Brunvold 8/2/22

What happens day-to-day in the life of a Research Scientist at NMD Pharma?

Read More
Newer Posts
Older Posts

NMD PHARMA A/S, CVR No. 36899069

Cookie Policy Terms of Use Privacy Policy US Expanded Access Policy

Follow us
LinkedIn X Facebook Instagram